Abbott Laboratories (ABT), Eli Lilly & Co. (LLY) And Why Diabetes Isn't Good for Health, But It Can Be for Your Portfolio
When I was six years old, something happened to me that I have never forgotten and will probably always live with.
Eli Lilly & Co (LLY)
Market is closed
News
- First
- << Previous
- 621 - 630
- Next >>
Apple Inc. (AAPL), Novo Nordisk A/S (ADR) (NVO) & 'The Most Sustainable Company in the World'
In January of 2012, Business Magazine released a list of the most sustainable companies in the world. You might be surprised to see who topped their list.
Eli Lilly & Co. (LLY): The Company Beats on Earnings Per Share
Eli Lilly & Co. (NYSE:LLY) notched revenue of $5.60 billion. The 12 analysts polled by S&P Capital IQ expected to see a top line of $5.68 billion on the same basis.
Merck & Co., Inc. (MRK): One Potential Roadblock For A Stock Runup
If you own Merck & Co., Inc. (NYSE:MRK) stock, you likely enjoyed the past couple of months.
Eli Lilly & Co. (LLY): Will The Big Bets Pay Off?
Tomorrow, Eli Lilly & Co. (NYSE:LLY) will release its latest quarterly results.
Eli Lilly & Co. (LLY), WellPoint, Inc. (WLP) & Five Must-Watch Earnings Reports in the Health-Care Sector This Week
If you haven't noticed, it's earnings season once again! Believe it or not, there are times when earnings reports slow down in frequency, but this is certainly not one of those times.
Vertex Pharmaceuticals Incorporated (VRTX), Gilead Sciences, Inc. (GILD): The Week, Biotech - Part Two
As I mentioned previously in Part 1, it was an incredibly busy week for the biotech sector.
Alkermes Plc (ALKS), Pfizer Inc. (PFE), Eli Lilly & Co. (LLY): These Biotech Investors Are Far From Depressed
The drug produced a statistically significant improvement in three different rating scales for depression compared to placebo.
Merck & Co., Inc. (MRK)'s Latest Drug and Strategy Concoctions
Merck & Co., Inc. (NYSE:MRK) reported a 7% decline in fourth-quarter profit after the patent expiry of Singulair on August 13, 2012, in the United States.
ACADIA Pharmaceuticals Inc. (ACAD): FDA Throws This Stock a Juicy Bone
I had recommended staying away from the company for now because it looked too risky with a long wait before the company could complete its second phase 3 trial for pimavanserin in patients with Parkinson...
- First
- << Previous
- 621 - 630
- Next >>
Billionaire Hedge Funds
